Baseline level and early on-treatment clearance of circulating mutant KRAS in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jacob E. Till, Aseel Abdalla, Neha Bhagwat, Taylor A. Black, Zhuoyang Wang, Stephanie S. Yee, Pier Federico Gherardini, Lacey J. Kitch, Cheryl Selinsky, Jaclyn Paige Lyman, Theresa LaVallee, George A. Fisher, Osama E. Rahma, Andrew H. Ko, Zev A. Wainberg, Robert A. Wolff, Eileen Mary O'Reilly, Robert H. Vonderheide, Mark H. O'Hara, Erica L. Carpenter
Institutions: Abramson Cancer Center, University of Pennsylvania, Parker Institute for Cancer Immunotherapy, Stanford Medicine, Stanford University, Dana-Farber Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Ronald Reagan UCLA Medical Center, UCLA Medical Center, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3167147059